Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
52 hedge funds and large institutions have $95.7M invested in Clearside Biomedical in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 15 reducing their positions, and 9 closing their positions.
118% more capital invested
Capital invested by funds: $43.8M → $95.7M (+$51.9M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
95% more call options, than puts
Call options by funds: $2.71M | Put options by funds: $1.39M
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
2% more funds holding
Funds holding: 51 → 52 (+1)
0.22% more ownership
Funds ownership: 2.06% → 2.28% (+0.22%)
13% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.17M |
| 2 |
Two Sigma Investments
New York
|
+$1.13M |
| 3 |
Two Sigma Advisers
New York
|
+$1.05M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$767K |
| 5 |
State Street
Boston,
Massachusetts
|
+$390K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIIC
AJU IB Investment Company
Seoul,
South Korea
|
-$1.55M |
| 2 |
Renaissance Technologies
New York
|
-$1.53M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$922K |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$408K |
| 5 |
CG
Carmignac Gestion
Paris,
France
|
-$375K |
CLSD Hedge Fund Activity: Q2 2021 in Review
52 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q2 2021, worth a combined $95.7M — up 118% from $43.8M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CLSD positions and 9 closed out — a net gain of 1 holder — while 13 added to existing stakes and 15 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.17M. The largest seller was AJU IB Investment Company, cutting an estimated $1.55M.
- 52 institutional investors held Clearside Biomedical (CLSD) as of Q2 2021, up from 51 in Q1 2021.
- Funds reported $95.7M of Clearside Biomedical stock for Q2 2021, up 118% quarter-over-quarter.
- 10 funds opened new Clearside Biomedical positions in Q2 2021 and 9 closed out, a net change of +1 holder.
- The largest Clearside Biomedical buyer in Q2 2021 was Vanguard Group, an estimated $1.17M added.
- The largest Clearside Biomedical seller in Q2 2021 was AJU IB Investment Company, an estimated $1.55M sold.
Based on aggregated 13F filings for Q2 2021.